Skip to content
Managedcaremag.com
  • Slimming Products
    • Medioxil24
    • Plus Kapseln
    • Figur Kapseln
    • Diaetolin
    • Liba Kapseln
    • Figur
    • Slimming Gummies
    • Keto-XP Fruchtgummis
    • BioXtrim Kritik
    • LB Slimming Gummies UK
    • KetoXplode
    • Theanex Kapseln
    • Mokka Brenner
    • Morning Complete US
    • Die Stoffwechsel Formel
    • Reduslim
    • Shape Kapseln Erfahrung
    • Theanex Avis
    • Dietoxone Gummies
    • Ketoviax
    • LB Slimming Gummies erfaring
    • ExiSlim
    • PureXKeto
    • Slim Vitax Gummies
    • TrimDrops
    • Slim Vitax Ervaring
    • Slimm Gummies
    • Nixol
  • Reviews
    • Redusugar
    • Liver Ignite
    • Cardione
    • Viscerex
    • Glucoslim Erfahrungen
    • Colon Broom
    • Floravia Kapseln
    • Autis Plus
    • Welltone Tropfen
    • Ark Drops
    • Bio X4
    • Circulaxil
    • NeuroRelax Kapseln
    • Testoprime
    • Neuro Boost
    • Neuro Boost test
    • Turkesterone
    • Igelstachelbart
    • Löwenzahn Elixier
    • Mikronährstoffe Testsieger
    • Testosteron Booster
    • Keto Diet
    • Lentinula Edodes
    • Chogan Parfum List
    • Mariendistel Kapseln
    • Kollagen Kapseln
    • Desoxyribose
    • Kollagen Pulver
    • Chogan Parfum
    • Hula Hoop Reifen
    • Enzymreiniger
    • Myo Inositol
    • Cranberry Kapseln
    • Ohrenreiniger
    • GLP1
    • Einlegesohlen
    • Grüne Helfer Pulver
    • Shiitake Pilze
    • Natürliches Antibiotika
    • Chondroitin
    • Akupressurmatte
    • Microneedling Zuhause
    • Haltungskorrektur
    • Haarvitamine
    • Exogene Ketone
    • Schneckenschleim Creme
  • Painkiller
    • Hondrox
  • Potency
    • C+ Kapseln
    • Viaciaxx Booster Fruchtgummis
    • Volt Kapseln
    • Volt Capsules
    • Viaciaxx
    • Erectax
    • Kamagra Oral Jelly
  • Magazine

Enzalutamide (Xtandi) More Effective Than Bicalutamid in Prostate Cancer Trial

March 4, 2024March 3, 2024 by Paul Lendner

Positive results from a phase 2 study of enzalutamide (Xtandi, Astellas US/Medivation, Inc.) compared with bicalutamide in patients with metastatic castration-resistant prostate cancer have been published online in Lancet Oncology.

The TERRAIN trial enrolled 375 patients in North America and Europe. The study enrolled patients with metastatic prostate cancer whose disease had progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue or after surgical castration. The study’s primary endpoint was progression-free survival (PFS), defined as the time from randomization to centrally confirmed radiographic progression, a skeletal-related event, the initiation of new antineoplastic therapy, or death, whichever occurred first. The trial was designed to compare enzalutamide 160 mg once daily with bicalutamide 50 mg once daily, the approved dose in combination with an LHRH analogue.

The study achieved its primary endpoint, demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide (hazard ratio, 0.44; P < 0.0001). The median PFS was 15.7 months in the enzalutamide group compared with 5.8 months in the bicalutamide group. The median treatment periods were 11.7 months in the enzalutamide group and 5.8 months in the bicalutamide group.

Serious adverse events were reported in 31.1% of enzalutamide-treated patients and in 23.0% of bicalutamide-treated patients. Individual grade-3 or higher adverse events largely occurred at a similar rate between the two treatment groups, with the exception of hypertension (7.1% for enzalutamide versus 4.2% for bicalutamide) and back pain (2.7% versus 1.6%). Grade-3 or higher cardiac events were reported in 5.5% of enzalutamide-treated patients compared with 2.1% of bicalutamide-treated patients. Two seizures were reported in the enzalutamide group and one in the bicalutamide group. The most common adverse events associated with enzalutamide therapy included fatigue, back pain, hot flush, hypertension, diarrhea, decreased weight, and pain in an extremity.

Enzalutamide is an androgen receptor inhibitor that acts on multiple steps in the androgen receptor signaling pathway within tumor cells. In preclinical studies, enzalutamide was shown to competitively inhibit androgen binding to androgen receptors, and to inhibit androgen receptor nuclear translocation and interaction with DNA. The treatment is approved by the FDA for patients with metastatic castration-resistant prostate cancer.

Source: Astellas US (link is external); January 13, 2016.

More Headlines

Breast Cancer Study Suggests New Uses for Old Drugs
Researchers find potentially “druggable” targets
FDA Delays Decision on Nausea Drug Granisetron (Sustol)
Application remains under review
Analysts Foresee Substantial Growth in Glioblastoma Treatment Market
Opdivo expected to supersede Avastin as standard of care for recurrent disease
FDA Rejects Drisapersen (Kyndrisa) for Duchenne’s Muscular Dystrophy
Agency cites insufficient efficacy data
One Brain-Dead, Five Injured in French Painkiller Trial
Authorities suspend further studies of cannabinoid drug
Survey: The Rocky Road to Value-Based Care
Health care leaders resist full commitment
Senate Investigation Finds More Infections From Dirty Scopes at Hospitals
FDA is slow to respond
Analysts Foresee U.S. Launch of Five New Pancreatic Cancer Drugs by 2021
High cost-to-benefit ratio will limit acceptance
Impulse Device Improves Long-Term Survival in Heart Failure Patients
All-cause mortality rate is 39% over six years

Paul Lendner
Paul Lendner

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.

Categories Uncategorized
Research Articles from Managed Care
Colorado hospitals unite combat prescription opioid abuse
Copyright © 2024 by Managedcaremag.com | Sitemap-DE | Sitemap-EN
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.